Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
about
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in CancerEfficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFRReverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor.Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms.IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cellsPrimary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.Stereotactic body radiotherapy for oligoprogressive cancer.Targeting the EGFR T790M mutation in non-small-cell lung cancer.A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition.Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-LetterLegomedicine-A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibody-Nanoparticle ConjugatesUnderstanding the Precision in "Precision Medicine"Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer
P2860
Q26741846-C5094C6E-CC4A-4ABA-A956-A0517AD58672Q33618558-FE873D24-7B06-4200-AD38-9FA0799321B1Q33880574-0F2173E2-5EE0-4C5A-B7AD-366BF7D43952Q37397842-4117FD0F-6B91-4386-9984-10E32B22E971Q37565357-7F34DC25-CF64-4DF0-87BD-5A0DBE4D0921Q37580344-47EC7D4B-B721-474A-BE66-4B7C83F67C0EQ37581008-C07D8512-F906-4B5E-90AA-0BDA80897372Q38682189-13EB9D24-3FD0-4BEE-8CD7-1F68B93F013BQ38707122-86D4E81F-E7CF-41DD-B21D-CC456072DD45Q38709287-A2515148-561E-4DA1-9AA1-71C65B636D76Q38745430-1C33519D-93A9-4312-91A6-9D5D770678AEQ38746756-17502C53-B324-4756-9CF2-698522677F23Q38756349-40C3AD85-AD35-4F4B-8606-485CDC52758CQ38935913-13396463-00E6-4F04-B3B9-F097C89A05FBQ39047294-BEEB06AB-0D69-41EC-8AF2-E09CE4DD423DQ41563298-FCF39EC5-C4EB-488A-8729-FB53707ABCE3Q42316038-EE7304F8-6CD3-4E4B-ACDC-1332DB37B1D1Q42319260-8E5D1A79-57E1-4485-BA35-3462833DF497Q42396908-A3445C84-AD77-46EE-AAE1-189E67EFBA7AQ47119773-E48C00D5-6DED-4ECF-B46A-D57A67F643BEQ47134648-B6100F2A-3639-46BB-B559-4E22A7A72BAAQ47260594-1B25444E-366E-4D4A-844A-06871564F765Q47671139-8B7D4610-C3E3-4F74-9D1C-FA8259E98D68Q48021721-2BD1B5F6-B2F7-4E56-B317-8B1B6811CC29Q58779784-51D9D16E-6E3A-48A6-A048-D3B27F8D913E
P2860
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@ast
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@en
type
label
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@ast
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@en
prefLabel
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@ast
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@en
P2093
P2860
P1433
P1476
Intratumoral Heterogeneity in ...... FR Tyrosine Kinase Inhibition.
@en
P2093
Chunxiao Xu
Cloud P Paweletz
Eiki Kikuchi
Fatima Al-Shahrour
Geoffrey I Shapiro
Inés Pulido
Jeffrey H Becker
Julián Carretero
Margaret Soucheray
Marzia Capelletti
P2860
P304
P356
10.1158/0008-5472.CAN-15-0377
P407
P577
2015-08-17T00:00:00Z